Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Randomized Controlled Clinical Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03902041 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT03902041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03902041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Randomized Controlled Clinical Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Shandong Provincial Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2019
Completion date
October 1, 2022
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell transplantation, eltrombopag